Zhi Tong Cai Jing·2026-03-30 15:25Core Viewpoint - Kanglong Chemical (300759.SZ) reported a revenue of 14.095 billion yuan for 2025, representing a year-on-year growth of 14.82%. However, the net profit attributable to shareholders decreased by 7.22% to 1.664 billion yuan, while the net profit excluding non-recurring items increased by 38.85% to 1.538 billion yuan. The company also proposed a cash dividend of 2 yuan per 10 shares (tax included) [1] Financial Performance - The company's total revenue reached 14.095 billion yuan, marking a 14.82% increase year-on-year [1] - Net profit attributable to shareholders was 1.664 billion yuan, reflecting a decrease of 7.22% [1] - Net profit excluding non-recurring items was 1.538 billion yuan, showing a significant increase of 38.85% [1] - Basic earnings per share stood at 0.9443 yuan [1] Strategic Initiatives - The company emphasizes a customer-centric service philosophy and leverages a fully integrated service platform to meet diverse global client needs [1] - There has been a notable performance in business with large pharmaceutical clients, indicating successful strategic client expansion [1] - The company is actively expanding its customer base and utilizing advanced technologies to empower new drug development, maintaining industry leadership in small molecules while rapidly developing new molecular types [1] - In the Chinese market, the company is implementing market strategies tailored to local conditions, resulting in rapid growth in business with Chinese clients [1] - The new order amount signed in 2025 increased by over 14% year-on-year [1]